Alerts will be sent to your verified email
Verify Email
SYNCOMF
|
Syncom Formulations
|
Jagsonpal Pharma
|
Bliss GVS Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
8.81 % | 12.82 % | 6.83 % |
|
5yr Avg Net Profit Margin
|
7.78 % | 8.95 % | 8.7 % |
|
Price to Book
|
4.61 | 6.66 | 1.59 |
|
P/E
|
27.4 | 26.26 | 15.66 |
|
5yr Avg Cash Conversion Cycle
|
84.02 Days | -0.27 Days | 186.56 Days |
|
5yr Average Interest Coverage Ratio
|
39.83 | 56.07 | 14.68 |
|
5yr Avg ROCE
|
12.74 % | 17.0 % | 13.27 % |
|
5yr Avg Operating Profit Margin
|
9.47 % | 10.5 % | 17.03 % |
|
5 yr average Debt to Equity
|
0.2 | 0.02 | 0.11 |
|
5yr CAGR Net Profit
|
19.56 % | 23.34 % | 4.24 % |
|
5yr Average Return on Assets
|
5.89 % | 9.97 % | 5.31 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
50.57 % | 67.65 % | 35.44 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | -1.06 % | 0.93 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Syncom Formulations
|
Jagsonpal Pharma
|
Bliss GVS Pharma
|
|---|